SCHEMBL3694372

SCHEMBL3694372

CC(C)C(C(=O)OC(C)(C)C)c1ccc(CBr)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
NFKB1 P19838 1/20 0.38
CYP2C19 P33261 1/20 0.38
LMNA P02545 2/20 0.37
PMP22 Q01453 1/20 0.37
NLRP3 Q96P20 1/20 0.37
BACE1 P56817 1/20 0.36
APP P05067 1/20 0.35
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
EPHX1 P07099 1/20 0.34
CA2 P00918 1/20 0.34
KMT2A Q03164 1/20 0.33
CES2 O00748 1/20 0.33
CES1 P23141 1/20 0.33
FFAR2 O15552 1/20 0.33
CXCR1 P25024 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3702175 0.87 CHRM2 (0.43) CYP3A4CYP1A2CYP2D6CYP2C9NFKB1
SCHEMBL3697239 0.85 CHRM2 (0.34) CYP3A4CYP1A2CYP2D6CYP2C9NFKB1
SCHEMBL3701806 0.85 ESR1 (0.34) CYP3A4CYP1A2CYP2D6CYP2C9NFKB1
SCHEMBL5216265 0.84 APP (0.45) CYP2C9NFKB1LMNAPMP22APP
SCHEMBL3702565 0.84 AAK1 (0.35) CYP3A4CYP1A2CYP2D6CYP2C9NFKB1
SCHEMBL1820503 0.83 LMNA (0.42) CYP3A4CYP1A2CYP2D6CYP2C9NFKB1
SCHEMBL8984189 0.83 KMT2A (0.49) LMNABACE1ESR1ESR2EPHX1
SCHEMBL3691178 0.83 CTSS (0.36) APPESR1ESR2
SCHEMBL1178706 0.81 ALOX5 (0.41) LMNAAPPKMT2AFFAR2
SCHEMBL10702507 0.80 FFAR2 (0.54) CYP3A4CYP1A2CYP2D6CYP2C9NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8987256-B2 Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-03-24 US disclosed
US-8987256-B2 Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-03-24 US disclosed
EP-2268625-B1 OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF Bayer Pharma AG (DE) 2012-05-16 EP disclosed
US-20110034450-A1 OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) 2011-02-10 US disclosed
US-20110034450-A1 OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) 2011-02-10 US disclosed
WO-2009127338-A1 OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034450-A1 OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF OTC, PC, HCAR2 CYP3A4 210/4885CYP1A2 119/4885CYP2D6 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.